Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00594646 · ClinicalTrials.gov registry record · Phase 4

HIV Non Occupational Post-Exposure Prophylaxis (PEP)

A Phase 4 study, sponsored by Fenway Community Health.

Completed
Registry status
Phase 4
Development phase
100
Enrollment target

NCT00594646: Completed Phase 4 study, sponsored by Fenway Community Health.

NCT00594646 is a Phase 4 study that has completed, run by Fenway Community Health. The registered enrollment target is 100 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00594646, a Phase 4 study, has completed, sponsored by Fenway Community Health.

COMPLETED
Registry status
Phase 4
Development phase
100 participants
Enrollment target

Study Summary

This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.

Primary Outcome

Pill counts performed at 14 and 28 days

Interventions

  • DRUG TRUVADA + Raltegravir

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2008-02
Est. Completion 2010-08
Phase Phase 4
Fenway Community Health

14 total trials

What the finished NCT00594646 record still lists

NCT00594646 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (81% lower).

The record links to 0 conditions, and to 1 intervention - of which TRUVADA + Raltegravir is the first listed.

NCT00594646 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00594646 about?

NCT00594646 is a clinical study titled "HIV Non Occupational Post-Exposure Prophylaxis (PEP)". This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.

What is the current status of trial NCT00594646?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2008-02. Estimated completion is 2010-08.

What interventions are being tested in trial NCT00594646?

The interventions under investigation include: TRUVADA + Raltegravir (DRUG).

Who is sponsoring clinical trial NCT00594646?

This trial is sponsored by Fenway Community Health, which has 14 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00594646's enrollment target sits among peer trials

100 770th of 2000 higher than 1,148 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00594646, the US trial registry maintained by the National Library of Medicine. NCT00594646 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.